Translate the text from Welsh to English.



 
Heddiw, ar ôl trafod y dystiolaeth a’i hystyried, mae'r Cyd\-bwyllgor ar Imiwneiddio a Brechu (JCVI) wedi gwneud dau argymhelliad i ymestyn y rhaglen frechu COVID\-19 ymhellach ar gyfer plant a phobl ifanc. 


Yn gyntaf, yn dilyn penderfyniad diweddar yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA) i gymeradwyo brechlyn COVID\-19 Pfizer\-BioNTech (Comirnaty®) mewn plant iau, mae'r JCVI wedi argymell y dylai plant 5 i 11 oed – plant sy’n perthyn i un o’r grwpiau “risg” neu sy'n gyswllt cartref i rywun sy’n imiwnoataliedig – gael cynnig dau ddos 10 microgram o'r brechlyn Pfizer\-BioNTech. Dylid gadael bwlch o wyth wythnos rhwng y dos cyntaf a'r ail ddos o’r brechlyn. Os bydd unigolyn wedi cael haint COVID\-19 yn ddiweddar, dylid gadael bwlch o bedair wythnos o leiaf rhwng unrhyw ddos o frechlyn a’r haint hwnnw.


Ar hyn o bryd, ar sail cydbwyso’r manteision a’r niwed posibl, mae'r JCVI o blaid brechu’r grŵp hwn. Hyd yma, tan y daw rhagor o wybodaeth a thystiolaeth i’r amlwg, nid yw'r JCVI wedi cynghori a ddylai plant 5 i 11 oed nad ydynt mewn categori “risg” gael eu brechu.


Yn ail, mae'r JCVI wedi argymell cynnig dos atgyfnerthu COVID\-19 i:


* Bob plentyn a pherson ifanc 16 i 17 oed
* Plant a phobl ifanc 12 i 15 oed sydd mewn grŵp risg clinigol neu sy'n gyswllt cartref i rywun sy’n imiwnoataliedig
* Plant a phobl ifanc 12 i 17 oed sy’n ddifrifol imiwnoataliedig ac sydd wedi cael trydydd dos sylfaenol.


Ni ddylai unigolion gael cynnig y dos atgyfnerthu hyd nes y bydd tri mis o leiaf ers iddynt gwblhau eu cwrs sylfaenol.


Yn ôl yr arfer, bydd gwybodaeth briodol am fanteision a risgiau posibl brechu ar gael i blant a phobl ifanc, rhieni a gwarcheidwaid er mwyn iddynt allu gwneud penderfyniad gwybodus ynglŷn â’r brechiad.


Rwyf wedi derbyn y cyngor hwn. Dilyn y dystiolaeth glinigol a gwyddonol yw ein bwriad, fel yr ydym wedi ei wneud ers dechrau'r pandemig.


Bydd GIG Cymru yn nodi plant a phobl ifanc 5 i 11 oed cymwys yn y grwpiau “risg” ac yn dechrau cynnig apwyntiadau yn y flwyddyn newydd. Bydd plant o dan 18 oed sy'n gymwys i gael dos atgyfnerthu yn cael apwyntiad pan fyddant yn gymwys.


Mae'r datganiad hwn yn cael ei gyhoeddi yn ystod y toriad er mwyn rhoi'r wybodaeth ddiweddaraf i'r Aelodau. Os bydd yr Aelodau am imi wneud datganiad pellach neu ateb cwestiynau am y mater hwn pan fydd y Senedd yn dychwelyd, byddwn yn hapus i wneud hynny.







Translation:


 
Today, following discussion and consideration of the evidence, the Joint Committee for Vaccination and Immunisation (JCVI) has made two recommendations to further expand the COVID\-19 vaccination programme for children and young people. 


Firstly, following the recent decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the Pfizer\-BioNTech COVID\-19 vaccine (Comirnaty®) vaccine in younger children, the JCVI has recommended children aged 5 to 11, who are in an “at\-risk” group or are the household contact of someone who is immunosuppressed should be offered two 10 micrograms doses of the Pfizer\-BioNTech vaccine with an interval of eight weeks between the first and second doses. The minimum interval between any vaccine dose and recent COVID\-19 infection should be four weeks.


At the current time, the JCVI considers the balance of potential benefits and harms is in favour of vaccination for this group. The JCVI has not as yet advised whether children aged 5 to 11, who are not in an “at\-risk” category should receive vaccination until more information and evidence is available.


Secondly, the JCVI has recommended offering a COVID\-19 booster dose to:


* All children and young people aged 16 to 17 years
* Children and young people aged 12 to 15 who are in a clinical risk group or who are a household contact of someone who is immunosuppressed
* Children and young people aged 12 to 17 years who are severely immuno\-compromised and who have had a third primary dose.


The booster dose should be offered no sooner than three months after completion of their primary course.


As always, appropriate information about the potential benefits and risks of vaccination will be made available for children and young people, parents and guardians to make an informed decision on vaccination.


I have accepted this advice. Our intention, as it has been from the start of the pandemic, is to follow the clinical and scientific evidence.


NHS Wales will identify eligible 5 to 11\-year\-olds in the “at risk” groups and begin offering appointments in the New Year, and under 18s who are eligible for a booster dose will receive an appointment when they become eligible.


This statement is being issued during recess in order to keep members informed. Should members wish me to make a further statement or to answer questions on this when the Senedd returns I would be happy to do so.